Gemtuzumab ozogamicin

Name: Gemtuzumab ozogamicin
Brand: MedChemExpress
SKU: HY-109539
Rating: 4.5 (1 reviews)

Cat. No.: HY-109539 Pureza: 95%: Ficha de datos
COA

SDS
Instrucciones de manejo
FAQs
Technical Support

Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic agent Calicheamicin (HY-19609). The antibody portion is Gemtuzumab (HY-P99971), and the drug-linker conjugate for ADC is N-Ac-γ-Calicheamicin-AcBut-NHS ester (HY-103688). Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML).

Para uso exclusivo en investigación. No vendemos a pacientes.

Gemtuzumab ozogamicin Estructura química

No. CAS : 220578-59-6

Tamaño	Stock	Cantidad
100 μg	En stock	Estimated Time of Arrival: December 31
200 μg	En stock	Estimated Time of Arrival: December 31
500 μg	En stock	Estimated Time of Arrival: December 31

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE Gemtuzumab ozogamicin

•bioRxiv. 2025 Aug 21:2025.08.17.670714. [Abstract]

Recomendaciones destacadas

•Related Small Molecules:

•Related Proteins:

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

In Vitro

Gemtuzumab ozogamicin (1-250 ng/mL ; 72 hours) has cell cytotoxicity in CD33-positive cells^[1].
Gemtuzumab ozogamicin is an ADC. After binding of the antibody to CD33 and subsequent internalization, Calicheamicin mediates cytotoxicity to CD33-positive myeloid cells primarily through induction of DNA damage and subsequent apoptosis^[1].
Gemtuzumab ozogamicin iproduces significant inhibition of colony formation in cultures of adult leukemic bone marrow cells^[3].
Gemtuzumab ozogamicin (5-100 μg/L) suppressed the cell growth of HL-60, NOMO-1, NB-3 and NKM-1 cell lines in a dose-dependent manner^[3].
Gemtuzumab ozogamicin (Compound GO) (1-100 nM, 24 h) induces dose-dependent capase activation at 10 and 100 nM in HL-60 cells^[4].
Gemtuzumab ozogamicin (1 nM-1 μM, 72 h) kills 95.05% of HL-60 and 42.61% of K-562 cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	CD33-positive and CD33-deficient cells (HL60, HL60R, Kasumi-1, MV4-11, MV4-11R, primary CD34-positive HSPCs and primary AML blasts)
Concentration:	0, 1, 5, 10, 25, 50, 100, 250 ng/mL
Incubation Time:	72 hours
Result:	Wildtype HL60 exhibited the highest sensitivity to GO (IC₅₀=1.37 ng/mL), and almost all HL60 cells died at 5 ng/mL concentration. HL60R, Kasumi-1, MV4-11 and MV4-11R showed similar sensitivity, with IC₅₀s of 2.28, 3.19, 3.63 and 5.36 ng/mL, respectively. IC₅₀ in CD33-negative HL60R, Kasumi-1, MV4-11 and MV4-11R cells also increased significantly to 95.53, 50.78, 72.74 and 66.8 ng/mL, respectively.

Ensayo clínico

Peso molecular

151000 (average)

No. CAS

220578-59-6

Appearance

Solid

Color

White to off-white

SMILES

[Gemtuzumab ozogamicin]

Envío

Shipping with dry ice.

Almacenamiento

-80°C, protect from light

Pureza y Documentación

Purity: 98.0%

Select Batch:

Ficha de datos (270 KB) SDS (251 KB)

COA (231 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Yi Liu, et al. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int J Cancer. 2022 Apr 1;150(7):1141-1155. [Content Brief]

[2]. Baron J, et al. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018;11(6):549-559. [Content Brief]

[3]. McGavin, J. K., & Spencer, C. M. (2001). Gemtuzumab ozogamicin. Drugs, 61(9), 1317–1324. [Content Brief]

[4]. Petrich, T., et al., (2010). In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin. European journal of nuclear medicine and molecular imaging, 37(5), 851–861. [Content Brief]